‘Important Steps To Ensure Equitable Care’: Medtronic Exec On Pulse Ox Panel

Sam Ajizian, chief medical officer of Medtronic’s patient monitoring operating unit, spoke to Medtech Insight about his reaction to a recent FDA panel meeting on ways to improve pulse oximetry accuracy and equity.

Caregiver securing pulse oximeter on the hand of a Black patient.
• Source: Shutterstock

A plan put forward by the US Food and Drug Administration and supported by most participants in a 2 February meeting of the agency’s anesthesiology and respiratory therapy devices advisory panel would more than double the minimum sample size needed in pulse oximeter clinical trials, as well as increasing the need for representation of people with darker skin tones. The move could be an important step for health equity, but what will it mean for device manufacturers?

Sam Ajizian, chief medical officer of Medtronic’s patient monitoring operating unit, spoke to Medtech Insight about his reaction to the...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Regulation

More from Policy & Regulation